23rd week of 2012 patent applcation highlights part 42 |
Patent application number | Title | Published |
20120141502 | ANTIBODIES SPECIFIC TO E6 PROTEINS OF HPV AND USE THEREOF - The subject invention provides an antibody composition for detecting E6 protein of at least one HPV strain in a sample. The subject antibodies may be used to detect oncogenic HPV E6 proteins in a sample, and the antibodies find use in a variety of diagnostic and therapeutic applications, including methods of diagnosing and treating cancer. Kits for performing the subject methods and containing the subject antibodies are also provided. Also disclosed in the present invention is a method of generating an antibody that specifically binds to amino-terminus of E6 proteins of at least two HPV strains. | 2012-06-07 |
20120141503 | Heavy Chain and Domain Antibodies - The present invention related to heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, suitable for use in the management of infections, in particular gastrointestinal tract. The present invention also relates to a delivery system comprising these heavy chain immunoglobulins or functional fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, and hosts comprising expression vectors encoding for these heavy chain immunoglobulins or functional fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof. The invention also related to food products and pharmaceutical preparations comprising the delivery system, and method for the preparation of food products according to the invention. | 2012-06-07 |
20120141504 | METHODS FOR TREATING INFLAMMATION USING B7-H4 POLYPEPTIDES AND FRAGMENTS THEREOF - The invention provides novel B7-H3 and B7-H4 polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides. | 2012-06-07 |
20120141505 | CD19-LIGAND AND USE - Provided herein are CD19-ligand (CD19-L) polypeptides and polynucleotides encoding such CD19-L polypeptides. Methods related to diagnosing and treating a disorder associated with CD19 positive B-cells in a patient using a CD19-L polypeptide are also provided. | 2012-06-07 |
20120141506 | TREATMENT OF NON-PROLIFERATIVE CYSTIC DISEASE - The present invention relates generally to the treatment of non-proliferative cystic disease of the breast. More particularly, the present invention relates generally to the treatment of non-proliferative cystic disease of the breast in BRCA1 mutant carriers. Accordingly, the invention relates to the use and application of compounds or agents, including somatostatin analogs, that inhibit insulin-like growth factor I (IGF-I) or insulin-like growth factor I receptor signaling for the treatment of non-proliferative cystic disease of the breast. The invention further relates to the use and application of these compounds or agents for the treatment of non-proliferative cystic disease of the breast in BRCA1 patients. The invention also relates to use of somatostatin analog SOM230 in treatment of non-proliferative cystic disease of the breast and more particularly, to use of somatostatin analog SOM230 in treatment of BRCA1 associated non-proliferative cystic disease. | 2012-06-07 |
20120141507 | TARGETING OF GLYCOPROTEIN THERAPEUTICS - Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes. | 2012-06-07 |
20120141508 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 2012-06-07 |
20120141509 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 2012-06-07 |
20120141510 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 2012-06-07 |
20120141511 | CLOSTRIDIAL TOXIN DERIVATIVES ABLE TO MODIFY PERIPHERAL SENSORY AFFERENT FUNCTIONS - A novel agent for the targeted control of a mammalian cell activity can be used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E, linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain, which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome; Domain T is the Translocation Domain, which translocates the agent from within the endosome across the endosomal membrane into the cytosol of the cell; and Domain E is the Effector Domain, which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell. | 2012-06-07 |
20120141512 | METHOD OF INCREASING IMMUNOLOGICAL EFFECT - A method of increasing immunological effect in a patient by administering an effective amount of a primary cell derived biologic to the patient, inducing immune production, blocking immune destruction, and increasing immunological effect in the patient. Methods of treating an immune target, treating a tumor, immune prophylaxis, and preventing tumor escape. | 2012-06-07 |
20120141513 | DEUTERATED FINGOLIMOD - This invention relates to novel compounds that are deuterated derivatives of fingolimod and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a lysophospholipid edg1 (S1P1) receptor agonist, such as fingolimod. | 2012-06-07 |
20120141514 | USE OF A CHEMICALLY-STABILIZED CHLORITE SOLUTION FOR INHIBITING AN ANTIGEN-SPECIFIC IMMUNE RESPONSE - Methods of using a stabilized chlorite solution to inhibit antigen-specific immune responses are disclosed. The stabilized chlorite solution, when administered to a mammal in need thereof, can prevent the presentation of antigens by antigen presenting cells. The stabilized chlorite solution therefore is useful in treating, inter alia, auto-immune diseases, treating diseases caused by an inappropriate immune response, treating lymphoproliferative disease and in inhibiting rejection in transplant patients. | 2012-06-07 |
20120141515 | Ig-pCONSENSUS GENE VACCINATION PROTECTS FROM ANTIBODY-DEPENDENT IMMUNE PATHOLOGY IN AUTOIMMUNE DISEASE - The disclosure provides methods and compositions useful for treating autoimmune diseases and disorders. For example, the disclosure demonstrates that hypergammaglobulinemia and subsequent accelerated kidney disease can be suppressed by Ig minigene-induced CD8 | 2012-06-07 |
20120141516 | COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE - The present invention provides compositions and methods for inducing an immune response in a subject. In particular, the present invention provides compositions comprising immunostimulatory ligands (ISL) and methods of inducing an immune response in a subject therewith. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications. | 2012-06-07 |
20120141517 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 2012-06-07 |
20120141518 | Human Parvovirus: Bocavirus - Provided herein are sequences of the genomes and encoded proteins of a new human parvovirus, Bocavirus-2, and variants thereof. Also provided are methods of detecting the Bocavirus-2 and diagnosing Bocavirus-2 infection, methods of treating or preventing Bocavirus-2 infection, and methods for identifying anti-Bocavirus-2 compounds. | 2012-06-07 |
20120141519 | REAGENTS AND METHODS FOR DETECTING INFLUENZA VIRUS PROTEINS - Two universally conserved sequences from influenza type A neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the N-terminus of the type A neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed. Quantitative analyses of NA using slot blot suggest that the antibodies can be used for NA antigen quantitation in vaccines. These represent the first time the antibody-based immunoassay can be used for NA quantitative determination. | 2012-06-07 |
20120141520 | RECOMBINANT SUBUNIT WEST NILE VIRUS VACCINE FOR PROTECTION OF HUMAN SUBJECTS - A West Nile virus vaccine for human use is described that preferably contains a recombinantly produced form of truncated West Nile virus envelope glycoprotein and aluminum adjuvant. The vaccine is acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. The vaccine is safe and effective for use in all healthy and at-risk populations. A pharmaceutically acceptable vehicle may also be included in the vaccine. | 2012-06-07 |
20120141521 | Immunogenic Compositions for Streptococcus agalactiae - The invention relates to immunogenic polypeptides derived from epitopes in a | 2012-06-07 |
20120141522 | RECOMBINANT PROTECTIVE PROTEIN FROM STREPTOCOCCUS PNEUMONIAE - The present invention discloses amino acid sequences and nucleic acid sequences relating to a | 2012-06-07 |
20120141523 | IMMUNOGENIC COMPOSITION COMPRISING ANTIGENIC S. AUREUS PROTEINS - The present application relates to an immunogenic composition comprising a fragment of a staphylococcal Isd protein such as IsdA, IsdB, IsdC or IsdH which comprises a NEAT domain. Fusion proteins comprising a NEAT domain of a first staphylococcal Isd protein and a NEAT domain from a second Isd protein are also disclosed as well as fusion proteins comprising a NEAT domain of a staphylococcal Isd protein involved in an iron/heme uptake system and a ligand binding domain of a staphylococcal extracellular component binding protein, for example ClfA, ClfB, SdrC, SdrD or SdrE. | 2012-06-07 |
20120141524 | ETHANOL EXTRACT OF ANTRODIA CAMPHORATA FOR INDUCING APOPTOSIS AND PREPARATION METHOD THEREOF - A preparation method for an ethanol extract of the fruiting body of | 2012-06-07 |
20120141525 | UNIVERSAL INFLUENZA VACCINE BASED ON RECOMBINANT MODIFIED VACCINE ANKARA VIRUS (MVA) - The present invention relates to a novel influenza vaccine, a novel plasmid for preparing the same and a novel dosage form comprising the same. The present invention in particular relates to a recombinant modified vaccinia Ankara (MVA) virus comprising and capable of simultaneously expressing a cassette of at least four foreign genes from influenza virus, specifically an avian influenza virus, wherein the said genes are inserted at a non-essential site, within the MVA genome. The invention further relates to a recombinant modified vaccinia Ankara (MVA) virus comprising and capable of simultaneously expressing a cassette of not less than two foreign genes from influenza virus, wherein the said genes are inserted at a non-essential site, within the MVA genome, with the provision that at least one foreign gene is either PB2 or M2e. The invention also provides composition and methods of making the universal influenza vaccine. | 2012-06-07 |
20120141526 | Nanoemulsion vaccines - The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods and compositions for the use of nanoemulsion compounds as mucosal adjuvants to induce immunity against environmental pathogens. Accordingly, in some embodiments, the present invention provides nanoemulsion vaccines comprising a nanoemulsion and an inactivated pathogen or protein derived from the pathogen. The present invention thus provides improved vaccines against a variety of environmental and human-released pathogens. | 2012-06-07 |
20120141527 | STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE - The invention provides structurally constrained viral peptides for use as therapeutic and vaccination agents, and for the production of antibodies for use in a number of applications including as therapeutic agents. The invention further provides methods and kits for use of the structurally constrained peptides and antibodies of the instant invention. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides. | 2012-06-07 |
20120141528 | LYOPHILIZED VIRAL FORMULATIONS - Provided herein are lyophilized viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The lyophilized viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage. | 2012-06-07 |
20120141529 | NOROVIRUS AND SAPOVIRUS ANTIGENS - Immunogenic compositions that elicit immune responses against | 2012-06-07 |
20120141530 | CANINE LYME DISEASE VACCINE - The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents. | 2012-06-07 |
20120141531 | COMPOSITION COMPRISING OIL DROPS - A composition comprises a water-soluble polymer matrix in which are dispersed droplets of oil, the composition comprising an active principle. The invention includes embodiments in which the active principle is included in at least some of the oil droplets as well as embodiments in which the oil droplets are free of active principle. The oil droplets are released as the matrix containing them dissolves in an aqueous medium. In one embodiment, the oil droplets are substantially immobilized in or by the matrix and the immobilizing feature is lost as the matrix dissolves in aqueous media. In certain embodiments, the oil drops may collectively be referred to as the oil phase of the composition of the invention. The product may be in the form of mini-beads. The oil phase and/or the polymer matrix may each include a surfactant. | 2012-06-07 |
20120141532 | Botulinum Toxin Formulation - Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects. | 2012-06-07 |
20120141533 | MYCOBACTERIAL MUTANTS INDUCING IL-12 - Provided are mycobacteria deleted in at least a portion of a region 3 ESAT-6-like gene cluster. Also provided are mycobacteria comprising a mutation in an roc-1 gene. Additionally, vaccines comprising these mycobacteria are provided. Further provided are methods of making a recombinant mycobacterium, methods of inducing an immune response in a mammal, methods of inhibiting IL-12 production in a mammal, and methods of stimulating IL-12 production in a mammal. Vaccine adjuvants are also provided, as are methods of inducing immunity to a target antigen in a mammal. | 2012-06-07 |
20120141534 | Vault Compositions for Immunization Against Chlamydia Genital Infection - Methods and compositions are provided herein for immunizing a subject against Chlamydial genital infection by administering to the subject an effective amount of a Chlamydial immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. In some aspects, the vault-like-particles are administered to the nasal mucosa. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity at mucosal surfaces while reducing inflammation associated with | 2012-06-07 |
20120141535 | PROCESS AND COMPOSITION FOR TREATMENT OF CANINE AND HUMAN LEISHMANIASIS - Process and immune chemotherapeutic/pharmaceutical composition for treatment of canine and human Leishmaniasis comprising a vaccine containing the FML antigen (Fucose Mannose-Ligand) and saponin adjuvant, used in association with chemotherapeutic agents, showing healing property, leaving the dogs previously infected, in the condition of sterile cure of visceral and tegumentary leishmaniasis, characterized by absence of parasites and the overall absence of | 2012-06-07 |
20120141536 | USE OF AN ADJUVANTED ALLERGY VACCINE FORMULATION FOR PARENTERAL ADMINISTRATION - The present invention relates to the use of a seasonal allergen composition for the manufacture of a vaccine formulation for preventing or treating allergy to the allergen composition in a subject by parenteral administration, wherein the vaccine formulation is administered in a dosage regimen comprising an up-dosing phase, wherein the up-dosing phase partly or wholly overlaps with the allergen season of the allergen composition. | 2012-06-07 |
20120141537 | ENHANCING T CELL ACTIVATION USING ALTERED MHC-PEPTIDE LIGANDS - Materials and Methods for identifying and using MHC molecule variants for activating self-reactive T cells in a peptide-specific manner, and their use to focus autoimmune cellular responses against diseases such as cancers and persisting viral infections, are described. | 2012-06-07 |
20120141538 | MODULATORS OF THE CX3CRI RECEPTOR AND THERAPEUTIC USES THEREOF - The present invention concerns modulators of the CX3CR1 receptor. More specifically, antagonists and agonists of the CX3CR1 receptor have been identified. These antagonists and agonists can be used for treating an inflammatory disorder, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a graft versus host disease, a behavioral disorder, a cicatrisation disorder, a viral infection, cancer or pain. They may also be used as an adjuvant in a vaccine composition. | 2012-06-07 |
20120141539 | METHODS FOR MODULATING TOLL-LIKE RECEPTOR MEDIATED ACTIVATION OF CELLS OF THE INNATE SYSTEM BY MODULATING XBP-1 ACTIVITY - The invention provides methods and compositions for modulating the activity of XBP-I protein, or a protein in a signal transduction pathway involving XBP-I to modulate the TLR-mediated activation of cells of the innate immune system. Enhancing the TLR-mediated activation of cells of the innate immune system enhance inflammatory responses. The present invention also pertains to methods for identifying compounds that modulate Toll-like receptor-mediated signaling. | 2012-06-07 |
20120141540 | Drug Delivery System - Red blood cells can be used as effective drug delivery systems when they contain proteins that do not readily diffuse out and which form affinity complexes with the desired drug. | 2012-06-07 |
20120141541 | SYNERGISTIC MIXTURE OF BETA-GALACTO-OLIGOSACCHARIDES WITH BETA-1,3 AND BETA-1,4/1,6 LINKAGES - The present invention relates to a nutritional composition comprising at least two different beta-galacto-oligosaccharides (BGOS) A and B wherein the majority of linkages between two galactose residues in BGOS A are beta 1,4 and/or beta 1,6, and the majority of linkages between two galactose residues in BGOS B are beta 1,3. Such mixtures show superior effects on the immune system and are particularly suitable for infant nutrition. | 2012-06-07 |
20120141542 | METHOD OF USING PUNICIC ACID TO ENHANCE IMMUNE RESPONSE AND PREVENT METABOLIC DISORDERS - Disclosed is a method of enhancing the immune response of an animal, including mammals and humans, to prevent or ameliorate immunoinflammatory diseases such as Inflammatory Bowel Disease, increase immune system development, maintain or increase CD4 | 2012-06-07 |
20120141543 | Carbon Nanotube Based Nanocomposites - Novel methods and compositions of nanocomposites are provided. One exemplary composition comprises a biocompatible polymer, such as polypropylene fumarate, and a carbon nanotube, such as a single walled carbon nanotube, an ultra-short carbon nanotube, or a substituted ultra-short carbon nanotube. An exemplary method comprises providing a biocompatible polymer and a carbon nanotube and combining a biocompatible polymer and a carbon nanotube to form a nanocomposite. Another exemplary method comprises providing a nanocomposite comprising a biocompatible polymer and a carbon nanotube and administering the composition to a subject. | 2012-06-07 |
20120141544 | Solid Dosage Form That Promotes Reliable Oral, Esophageal and GI Transit - A solid dosage form designed to facilitate rapid and reliable oral, esophageal and GI transit has a surface area of the contact patch, i.e., the area of contact between the dosage form and the bodily surface reduced. The dosage form can be an asymmetric oral dosage unit containing a bioactive, the dosage unit being asymmetric with respect to a rotational axis perpendicular to a longitudinal axis of the dosage form, the rotational axis being located substantially at a mid point along the longitudinal axis. The dosage unit may have an outer surface ridged or dimpled or have at least one annular ring so as to reduce the contact patch of the dosage unit with a flat surface compared to non-ridged dosage unit of the same size and shape. The oral dosage unit can also have a spherical shape with or without ridges and/or dimples. Dies for forming these oral dosage units have, in a closed state, a cavity having a shape corresponding to the oral dosage unit. | 2012-06-07 |
20120141545 | Solid Dosage Form That Promotes Reliable Oral, Esophageal and GI Transit - A solid dosage form designed to facilitate rapid and reliable oral, esophageal and GI transit has a surface area of the contact patch, i.e., the area of contact between the dosage form and the bodily surface reduced. The dosage form can be an asymmetric oral dosage unit containing a bioactive, the dosage unit being asymmetric with respect to a rotational axis perpendicular to a longitudinal axis of the dosage form, the rotational axis being located substantially at a mid point along the longitudinal axis. The dosage unit may have an outer surface ridged or dimpled or have at least one annular ring so as to reduce the contact patch of the dosage unit with a flat surface compared to non-ridged dosage unit of the same size and shape. The oral dosage unit can also have a spherical shape with or without ridges and/or dimples. Dies for forming these oral dosage units have, in a closed state, a cavity having a shape corresponding to the oral dosage unit. | 2012-06-07 |
20120141546 | OIL-BASED PREPARATION - The present invention relates to an oil-based preparation comprising a triazine which is active against parasitic protozoans and an anthelmintic cyclodepsipeptide, which preparation is particularly suitable for the oral application of the active substance combination in animals. | 2012-06-07 |
20120141547 | METHODS OF MAKING CELL SHEETS, TISSUE SHEETS AND TISSUE ENGINEERED BLOOD VESSELS - Methods of making cell sheets, tissue sheets and tissue-engineered blood vessels are provided. The methods include culturing cells on a nanoimprinted coated scaffold under hypoxic conditions to form an aligned cell sheet and then removing the aligned cell sheet from the scaffold. The cell sheets, tissue sheets and tissue-engineered blood vessels made the methods are also disclosed. The cell sheets, tissue sheets and tissue-engineered blood vessels may be implanted in subjects to treat a variety of conditions. | 2012-06-07 |
20120141548 | NOVEL FORMULATION OF MELOXICAM - The present invention relates to methods for producing particles of meloxicam using dry milling processes as well as compositions comprising meloxicam, medicaments produced using meloxicam in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of meloxicam administered by way of said medicaments. | 2012-06-07 |
20120141549 | OLIGONUCLEOTIDES TARGETING ASTHMA INFLAMMATION PROCESSES - The present invention relates to methods and compositions for inhibiting inflammatory processes (such as asthma) in the lungs, wherein oligonucleotides targeting IgE receptors and NfkappaB are administered via an aerosolized microsphere formulation. | 2012-06-07 |
20120141550 | SYSTEM AND METHOD FOR DELIVERY OF DNA-BINDING CHEMOTHERAPY DRUGS USING NANOPARTICLES - System and method for loading the front line anticancer drug, doxorubicin (DOX) onto DNA-capped gold nanoparticles whose duplex DNA has been designed for specific DOX intercalation. Since each AuNP contains about 108 high affinity drug sites, this design allows for a high local DOX concentration on the particle. Drug binding was confirmed by monitoring the increase in DNA melting temperature, the shift in the plasmon resonance maximum, and the increase in the NP hydrodynamic radius as a function of [DOX]/[DNA] ratio. The feasibility of the nanoparticles as a drug delivery system was demonstrated by showing that particle-bound DOX could be transferred to a target DNA. | 2012-06-07 |
20120141551 | APTAMER BIOCONJUGATE DRUG DELIVERY DEVICE - A delivery device for an active agent comprises nanoparticles based on a biopolymer such as starch. The delivery device may also be in the form of an aptamer-biopolymer-active agent conjugate wherein the aptamer targets the device for the treatment of specific disorders. The nanoparticles may be made by applying a high shear force in the presence of a crosslinker. The particles may be predominantly in the range of 50-150 nm and form a colloidal dispersion of crosslinked hydrogel particles in water. The biopolymer may be functionalized. The aptamer may be conjugated directly to the cross-linked biopolymers. The active agent may be a drug useful for the treatment of cancer. The delivery device survives for a period of time in the body sufficient to allow for the sustained release of a drug and for the transportation and uptake of the conjugate into targeted cells. However, the biopolymer is biocompatible and resorbable. | 2012-06-07 |
20120141552 | ULTRASOUND TECHNOLOGY TO CONTROL THE SPATIAL ORGANIZATION OF CELLS AND PROTEINS IN ENGINEERED TISSUES - The present invention is directed to methods of inducing spatial organization of cells an in vitro culture system using ultrasound technology. The invention is further directed to methods of inducing extracellular matrix remodeling and neovessel formation in an in vitro culture system and generating vascularized engineered tissue constructs using ultrasound technology. | 2012-06-07 |
20120141553 | BIOCOMPATIBLE POLYMER FIBRES FOR NEUROIMPLANTS - The present invention relates to a neuroimplant. The neuroimplant comprises biocompatible polymer fibres; the polymer fibres are grouped in a parallel arrangement, and the group of fibres is flexible. The present invention also relates to the use of the neuroimplant to facilitate the repair of damaged brain tissue. | 2012-06-07 |
20120141555 | Compound and device for treating bone and/or cartilage defects - The present invention relates to compositions devices and methods for treating bone and/or cartilage defects, and a method for manufacturing such a composition or device. In a certain embodiment, the invention provides a device and/or composition for treating bone and/or cartilage defects, having at least one collagen, for example of animal origin, and further containing at least one substance having an osteo-inductive or chondro-inductive activity, at least one differentiation and/or growth factor having osteo-stimulative and/or chondro-stimulative effect, and at least one filling material, in which the composition is in the form of a lyophil. | 2012-06-07 |
20120141556 | LYOPHILIZING COMPOSITION OF DRUG-ENCAPSULATING POLYMER MICELLE AND METHOD FOR PREPARATION THEREOF - Provided are a composition for preparing a lyophilized preparation, comprising a drug-encapsulating polymer micelle and saccharides and/or polyethylene glycol as a stabilizing agent, a lyophilized preparation and a process for producing them. The lyophilized preparation thus provided is easily restructured to an aqueous preparation using an aqueous medium. | 2012-06-07 |
20120141557 | HIGHLY-MINERALIZED OSTEOGENIC SPONGE COMPOSITIONS AND USES THEREOF - Osteogenic sponge compositions having enhanced osteoinductive properties for use in bone repair are described. The compositions include a quickly resorbable porous carrier, a more slowly resorbed mineral scaffold and an osteogenic factor, preferably a bone morphogenetic protein. The compositions enable increased osteoinductive activity while retaining a reliable scaffold for the formation of new bone at an implant site. Methods for therapeutic use of the compositions are also described. | 2012-06-07 |
20120141558 | ALGINATE-BASED NANOFIBERS AND RELATED SCAFFOLDS - Alginate nanofibers, scaffolds that include alginate nanofibers, implantable devices that include alginate nanofibers, and methods for making the alginate nanofibers by electrospinning. | 2012-06-07 |
20120141559 | BIO-MEMBRANE FOR TISSUE REGENERATION - A bio-membrane with angiogenic activity for implant in tissue regeneration and repair, including bone reconstruction and the repair of skin and soft tissue lesions is described, essentially constituted by a gel able to provide support and growth and/or differentiation and/or angiogenic factors for the full in vivo functionality of the cell, containing also mesenchymal stem/precursor cells, an implant device for reconstructive surgery of bone tissue, of skin and soft tissue lesions which comprises the bio-membrane, and a method for its obtainment. Use of the gel alone for tissue regeneration and of adhesive plasters that comprise it is also described. | 2012-06-07 |
20120141560 | TUMOR AND INFECTIOUS DISEASE THERAPEUTIC COMPOSITIONS - A pharmaceutical composition comprising lectins is anti-tumorigenic and anti-viral, bacterial or protozoan. The composition, termed BiOmune is also useful for imaging, diagnosis and therapy of cancer. | 2012-06-07 |
20120141561 | NANOPARTICULATE CANDESARTAN CILEXITIL COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured (nanoparticulated) Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Candesartan Cilexetil is a prodrug, is hydrolyzed to Candesartan during absorption from the gastrointestinal tract. Candesartan is a selective AT1 subtype angiotensin II receptor antagonist. | 2012-06-07 |
20120141562 | CELL COATED IMPLANTABLE DEVICE - The present invention relates, in general, to a cell-coated implantable medical device and, in particular, to an implantable medical device the blood-contacting surfaces of which are coated with endothelial progenitor cells (EPCs). In a preferred embodiment, the medical device is a titanium or titanium alloy-based medical device. | 2012-06-07 |
20120141563 | PHARMACEUTICAL COMPOSITION INCLUDING A DHA ESTER TO BE ADMINISTERED PARENTERALLY - The present invention relates to a pharmaceutical composition to be parenterally administered, including submicronic ester particles of docosahexaenoic acid, dispersed in an aqueous phase using a mixture of at least two surfactants selected from among a) at least one polyoxyethylene fatty acid ester and b) at least one phospholipid derivative. The present invention also relates to the method for preparing said pharmaceutical composition. | 2012-06-07 |
20120141564 | COMPOSITIONS AND METHODS OF TREATING INFLAMMATION - A method of treating a lymphocyte mediated inflammation in a subject including administering a therapeutically effective amount of a cell delivery composition to the subject, the cell delivery composition of the application including an immunosuppressive cell and a plurality of targeting moieties that bind to endothelial cell adhesion molecules expressed by endothelial cells as a result of a lymphocyte mediated inflammatory response in the subject, the targeting moieties coated on and linked to the immunosuppressive cell and enhancing adherence of the immunosuppressive cell to an endothelial cell at a site of lymphocyte mediated inflammation when administered to the subject systemically, wherein the cell delivery composition, suppresses lymphocyte mediated inflammation in the subject. | 2012-06-07 |
20120141565 | GLYCEROSOMES AND USE THEREOF IN PHARMACEUTICAL AND COSMETIC PREPARATIONS FOR TOPICAL APPLICATIONS - The present invention relates to vesicles for topical delivery of drugs and cosmetics, named glyceromes and characterized by high content of glycerol. The invention further relates to pharmaceutical formulations and cosmetic products containing glycerosomes. | 2012-06-07 |
20120141566 | Protein Stabilized Antimicrobial Composition Formed by Melt Processing - A method for forming an antimicrobial composition that includes mixing an antimicrobially active botanical oil (e.g., thymol, carvacrol, etc.) and protein within a melt blending device (e.g., extruder) is provided. Despite the problems normally associated with melt processing proteins, the present inventors have discovered that the processing conditions and components may be selectively controlled to allow for the formation of a stable, melt-processed composition that is able to exhibit good mechanical properties. For example, the extrusion temperature(s) and shear rate employed during melt blending are relatively low to help limit polypeptide dissociation, thereby minimizing the impact of aggregation and embrittlement. While the use of such low temperature/shear conditions often tend to reduce mixing efficiency, the present inventors have discovered that a carrier fluid may be employed to enhance the ability of the botanical oil to flow into the internal structure of the protein where it can be retained in a stable manner. The composition is also typically anhydrous and generally free of solvents. In this manner, the protein will not generally disperse before use and prematurely release the botanical oil. | 2012-06-07 |
20120141567 | Melt Processed Antimicrobial Composition - A method for forming a composition that includes mixing an antimicrobially active botanical oil (e.g., thymol, carvacrol, etc.) and a modified starch polymer within a melt blending device (e.g., extruder) is provided. Unlike the problems associated with proteins, the use of starch polymers allows for a greater degree of flexibility in the processing conditions and is still able to achieve good properties in the resulting composition. The present inventors have also discovered that a plasticizer may be employed to facilitate melt processing of the starch, as well as to enhance the ability of the botanical oil to flow into the internal structure of the starch where it can be retained in a stable manner. The composition is also typically generally free of solvents. In this manner, the starch will not generally disperse before use and prematurely release the botanical oil. Due to the water sensitivity of the modified starch, however, it may be subsequently dispersed by moisture when it is desired to release the botanical oil. | 2012-06-07 |
20120141568 | FIBROUS SUBSTRATE WITH A SOLID HYPOHALITE PRECIPITATE FORMED THEREIN AND PROCESS OF MAKING - A cleaning substrate which comprises at least one layer of a solid hypohalite precipitate, wherein the hypohalite precipitate is formed in situ on the layer of substrate material. A process for making a fibrous cleaning substrate comprising the steps of: a) providing at least one layer of fibrous material; b) exposing the fibrous layer to an aqueous alkaline earth salt solution; c) treating the fibrous layer with a hypochlorite solution; d) allowing the aqueous alkaline earth salt solution combine with the hypochlorite solution to form a solid hypochlorite precipitate around the fibers in the fibrous material and a liquid phase, and e) removing at least 65% of the liquid phase from the fibrous substrate. | 2012-06-07 |
20120141569 | Wipe Coated with a Botanical Composition having Antimicrobial Properties - A wipe that contains a fibrous web on which is coated an antimicrobial composition is provided. The composition includes a botanical oil derived from a plant (e.g., thymol, carvacrol, etc.). Because the botanical oil is volatile and tends to evaporate and lose efficacy during storage and prior to use, a protein is also employed in the composition to enhance long term stability of the oil and, in turn, its antimicrobial efficacy. The protein is “film-forming” in the sense that it tends to form a substantially continuous film when coated onto a surface of the fibrous web. Because such proteins are typically stiff and brittle in nature, a continuous film would restrict the ability of the fibers to move and bend, thereby reducing web flexibility and drape. Thus, it is typically desired that the antimicrobial composition form a discontinuous coating on the fibrous web. In this regard, the present inventors have surprisingly discovered that the addition of an organopolysiloxane can help achieve such a discontinuous coating without adversely impacting the ability of the protein to stabilize the botanical oil. The organopolysiloxane may also enhance the softness and overall handfeel of the wipe. | 2012-06-07 |
20120141570 | PAPER PRODUCT WITH DISINFECTING PROPERTIES - A paper product having an antimicrobial composition dispersed with the substrate is provided. In particular, a paper towel such as those found in public washrooms or institutions comprises an antimicrobial composition. The substrate can also be a facial tissue, kitchen towel, serviette or any type of personal hygiene product. The antimicrobial composition preferably comprises a phenol-derived antimicrobial agent. The paper products of the present invention appear dry to the touch. | 2012-06-07 |
20120141571 | Wipe Coated with a Botanical Emulsion having Antimicrobial Properties - An oil-in-water emulsion that is environmentally friendly and also exhibits antimicrobial activity is provided. More specifically, the oil phase of the emulsion includes a botanical oil derived from a plant (e.g., thymol, carvacrol, etc.). Because the botanical oil tends to leach out of the emulsion during storage and before it is used in the desired application, a water-dispersible polymer is also employed in the aqueous phase of the emulsion to enhance long term stability of the oil and, in turn, antimicrobial efficacy. Without intending to be limited by theory, it is believed that the water-dispersible polymer can effectively encapsulate the botanical oil within the emulsion and inhibit its premature release. Once the emulsion is formed, water can then be removed so that it becomes a substantially anhydrous concentrate. In this manner, the water-dispersible polymer will not generally disperse before use and prematurely release the botanical oil. When it is desired, moisture may simply be re-applied to the concentrate to disperse the polymer and activate the release of the botanical oil. Of course, to provide the optimum degree of biocompatibility, the water-dispersible polymer is also a “biopolymer” that is biodegradable and/or renewable. | 2012-06-07 |
20120141572 | Surface Coating for Biomedical Implants and Electrodes - An implantable device is described based on an implant having a textured outer surface of polymer material with limited transparency. A smooth outer polymer coating covers and cross-links with the textured outer surface to form a coated implant of greater transparency than the polymer material of the implant. | 2012-06-07 |
20120141573 | Cell Lines That Secrete Anti-Angiogenic Antibody-Scaffolds and Soluble Receptors and Uses Thereof - The invention provides nucleic acid and polypeptide sequences encoding antibody based scaffolds such as full antibodies, antibody Fab fragments, single chain antibodies, soluble VEGF receptor-Fc fusion proteins, and/or anti-angiogenic PDGF receptors. Also encompassed are cell lines encoding such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors. The invention also provides encapsulated cell therapy devices that are capable of delivering such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors as well as methods of using these devices to deliver the anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors to medically treat disorders in patients, including ophthalmic, vascular, inflammatory, and cell proliferation diseases. | 2012-06-07 |
20120141574 | Process for Manufacturing Chewable Dosage Forms for Drug Delivery and Products Thereof - A palatable, edible soft chewable medication vehicle for delivery of a pharmaceutically acceptable active ingredient, such as a drug, to an animal or human subject. The edible soft chews contain only food grade or better inactive ingredients, and preferably do not contain ingredients of animal origin. Processes for manufacturing the edible soft chews do not require the use of heat or the addition of water during mixing of active and inactive ingredients, provide stable concentrations of the active ingredient, and produce chews of consistent weight and texture. | 2012-06-07 |
20120141575 | Collagen For Use In The Treatment Of Skin Diseases - The invention relates to collagen for use in the treatment of inflammatory and degenerative skin diseases and damage to the skin connected therewith, such as in particular in the treatment of psoriasis, dermatitis, neurodermitis, rosacea, urticaria (hives), pruritus (itching), skin eczema and actinic keratosis. In particular, the invention relates to freeze-dried collagen in the form of layered dressings, sheets, pads or masks for the aforementioned use. | 2012-06-07 |
20120141576 | Treatment of Dermatologic Skin Disorders - Retinal and its derivatives are incorporated with liposomes in therapeutic compositions for topical application to prevent or alleviate the conditions and symptoms of cosmetic and dermatologic disorders are described as follows. In particular, retinal and its derivatives are combined with liposomes to increase the penetration of the retinal into the skin, to provide hydration of the skin during treatment, to reduce irritation of the skin during the application of the retinal, for use as a chemical skin peel and other embodiments and uses. The present invention includes utilizing retinol products, and particularly retinal in combination with liposomes each of these embodiments and uses separately as well as in combinations with one another. | 2012-06-07 |
20120141577 | LINEAR EXPRESSION CASSETTE VACCINES - The disclosure relates to a linear expression cassette (LEC) as a nucleic acid based vector for producing a gene product of interest. Methods of preparing a disclosed LEC, as well as methods for its use to express a gene product in a subject, are also described. An LEC may be used in an animal or human subject to produce a therapeutic and/or immune response in the subject, such as an immunized state. | 2012-06-07 |
20120141578 | COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES - Anti-cancer compositions and methods are described herein. In particular, compositions including one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described. Methods for treatment of pathological conditions particularly cancer, in a subject using one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described herein. | 2012-06-07 |
20120141579 | Cytotoxic T Lymphocyte Inducing Immunogens for Prevention Treatment and Diagnosis of Cancer - The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as lung carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against lung and other cancers. | 2012-06-07 |
20120141580 | CAPSULE FORMULATIONS CONTAINING LANTHANUM COMPOUNDS - The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or lanthanum hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The capsules of the present invention dissolve at a similar rate before and after storage. The oral pharmaceutical capsules of the present invention can be administered to treat a patient at risk for or suffering from hyperphosphatemia, at risk for or suffering from chronic kidney disease (CKD), at risk for or suffering from soft tissue calcification associated with CKD, or at risk for or suffering from secondary hyperparathyroidism. | 2012-06-07 |
20120141581 | CAPSULE AND POWDER FORMULATIONS CONTAINING LANTHANUM COMPOUNDS - The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism. | 2012-06-07 |
20120141582 | Thixotropic Oil Based Vehicle for Pharmaceutical Compositions - The present invention relates to a novel thixotropic oily vehicle comprising between about 0.2% to about 5% (w/w) of a colloidal silica and between about 0.2% to about 5% (w/w) of a hydrophilic polymer in an edible oil. The interaction between the hydrophylic polymer and the colloidal silica in the above concentration ranges confers thixotropy and a low viscosity under shear on the solution. The invention also relates to capsules filled with the above thixotropic solution used as a fill mass. | 2012-06-07 |
20120141584 | Multilayer Minitablets - Multilayer minitablets for oral administration of an active pharmaceutical ingredient which release the active pharmaceutical ingredient at different pH ranges and/or in different release profiles are described. | 2012-06-07 |
20120141585 | IMMUNOMODULATORY COMPOSITIONS COMPRISING A POLYMER MATRIX AND AN OIL PHASE - A pharmaceutical composition comprising a water-soluble polymer matrix in which are dispersed droplets of oil, the composition comprising at least one immunomodulator selected from an adjuvant, an antigen or a combination thereof. A method of manufacturing shaped compositions comprises mixing an aqueous solution of a water-soluble polymer with an oil-based liquid to form a water-in-oil emulsion, at least one of the aqueous solution and the oil-based liquid comprising an antigen or an adjuvant or a combination thereof, and then causing or allowing the resultant suspension to solidify into one or more beads or other shaped elements | 2012-06-07 |
20120141586 | THROMBIN RECEPTOR ANTAGONIST AND CLOPIDOGREL FIXED DOSE TABLET - The present invention provides for a pharmaceutical formulation which comprises a) a compound of the formula (I): SCH 530348 or the bisulfate salt thereof; b) clopidogrel; and c) silicified microcrystalline cellulose. | 2012-06-07 |
20120141587 | COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF POST-OPERATIVE ORGAN OR TISSUE INFLAMMATION - Compositions, methods and kits for treatment or prevention of post operative organ or tissue inflammation are provided. The compositions contain an effective amount for local delivery, of an anti-inflammatory agent, alone or in combination with other pharmacologic agents, embedded within a polymeric matrix or gel. The polymeric matrix or gel may be a formed from natural or synthetic precursor components. The compositions are applied locally to an organ or tissue for the treatment or prevention of post inflammation resulting from surgical intervention. | 2012-06-07 |
20120141588 | DENTIFRICE COMPOSITIONS CONTAINING CALCIUM SILICATE AND A BASIC AMINO ACID - An oral care composition includes an effective amount of a basic amino acid in free or salt form; and an effective amount of calcium silicate particles. The calcium silicate particles have an average diameter of less than about 5 microns, such that they can occlude dentinal tubules of the teeth. An oral care method includes applying the composition to an oral cavity of a subject to reduce or inhibit hypersensitivity of the teeth and to achieve other benefits. | 2012-06-07 |
20120141589 | PARTICLES FOR DRUG DELIVERY AND OTHER APPLICATIONS - The present invention generally relates to particles for drug delivery and other applications. In one aspect, the present invention relates to a technique for reacting precursor compounds in the presence of a pharmaceutically-active agent to form product (e.g., in the form of particles) in which the agent is substantially contained within the product, and the product is soluble within typical gastric fluid of a mammal. In another aspect, the present invention is generally directed to particles comprising an inorganic pharmaceutically acceptable carrier, such as CaCO | 2012-06-07 |
20120141590 | Technology for the Preparation of Microparticles - Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions. | 2012-06-07 |
20120141591 | Drug Delivery Nanocarriers Targeted by Landscape Phage - A targeted drug delivery nanocarrier and a method of forming the same is disclosed herein. The targeted drug delivery nanocarrier includes a plurality of amphipathic molecules forming a carrier particle having a plurality of drug molecules contained therein. A targeted landscape phage protein assembly is complexed to the carrier particle preferably using the unique method disclosed herein. The targeted landscape phage protein assembly displays a binding peptide that is selected to specifically and selectively bind to a target site. The method for forming targeted drug delivery nanocarriers includes the steps of obtaining a plurality of bacteriophage displaying a binding peptide for a desired target site, treating the bacteriophage with a denaturing agent, mixing the treated bacteriophage with a plurality of carrier particles and purifying the mixture to obtain a plurality of targeted drug delivery nanocarriers. | 2012-06-07 |
20120141592 | CONTROLLED-RELEASE GRANULAR COMPOSITIONS CONTAINING MESALAZINE AND PROCESS FOR THE MANUFACTURE THEREOF - The present invention refers to controlled release granular compositions of mesalazine and their use in the treatment of inflammatory pathologies of the intestinal tract. The aforesaid granular compositions comprise: a) a central core comprising an inert substrate; b) an intermediate layer comprising mesalazine and one or more physiologically acceptable excipients; c) a gastro-resistant coating. The present invention then refers to a process for obtaining the aforesaid granular compositions. | 2012-06-07 |
20120141593 | METHODS OF INCREASING PRODUCTIVITY IN OLDER SOWS WHILE DECREASING FEED INTAKE - The present invention provides methods for feeding older sows that beneficially reduce feed intake in older sows, yet improve pig survival and weaning weight of pigs from older sows. | 2012-06-07 |
20120141594 | COMPOSITION WITH ANTI-INFLAMMATORY, PROTEIN SYNTHESIZING, ENZYME DEFICIENCY ACTIVATING GENETIC THERAPY, AND ANTI-CANCER ACTIVITY AND METHODS OF USE - A composition for treating damaged tissue and promoting healthy tissue growth, healing and tissue regeneration, wherein said composition comprises an extracellular matrix compound, a surface-active lipid, one or more enantiomerically pure L-amino acids or glycine, a hydrophilic surfactant with a high HLB, as well as vitamins, minerals or trace elements. Not only does it maintain good health, but the components are non-intrusive, bio-safe, non-coalescent and can mimic normally occurring stem-cells within a body. When applied to diseased tissues, the subject compositions can stimulate, facilitate, and accelerate protein synthesis for the regeneration of diseased organs and tissues. The healing efficacy of these tissue components gives us further appreciation of the protective action of human tissue over and above and other than the immune protective system or perhaps an integral component part of the immune system. | 2012-06-07 |
20120141595 | UMBILICAL CORD AMNIOTIC MEMBRANE PRODUCTS - Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM. | 2012-06-07 |
20120141596 | Multi-Purpose Bio-Material Composition - The present invention relates to a multi-purpose bio-material. One preferred embodiment of the present invention generally comprises KH | 2012-06-07 |
20120141597 | FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER - The present invention relates to the use of hydrazone compounds and copper for controlling the growth of fungi. | 2012-06-07 |
20120141598 | BROAD SPECTRUM DECONTAMINATE AND DISPERSEMENT SYSTEM - The invention relates to a composition for decontaminating a toxin present in a polar or non-polar matrix. The composition includes (a) at least one activator that generates reactive oxygen species when reacted with an oxygen radical donator, and (b) at least one oxygen radical donator to react with the activator to create reactive oxygen species. The composition may also include one or more oxidizing agents that include reactive oxygen species. | 2012-06-07 |
20120141599 | Regulation Of Bone Growth Using Zeolite In Combination With Bone Graft Substitutes - Medical implants such as bone graft substitutes that include one or more cations are delivered in a local environment to promote osteogenesis. Zeolite loaded with a metal cation in combination with an implant such as a bone graft substitute can be used as an implant in the body to regulate protein transcription and translation. Also disclosed are methods of promoting osteogenesis in a patient in need thereof, methods for modulating bone formation and mineralization by implanting in a patient a medical implant comprising ion-exchangeable cations, and methods of regulating BMP gene expression in bone cells in a patient by controlling the delivery of certain cations through ion-exchange via a zeolite incorporated in a bone substitute implanted in a patient so that BMP gene expression can be upregulated or downregulated appropriately. | 2012-06-07 |
20120141600 | Compositions Having a High Antiviral and Antibacterial Efficacy - Antimicrobial compositions having a rapid antiviral and antibacterial effectiveness, and a persistent antiviral effectiveness, are disclosed. The anti-microbial compositions contain (a) an antimicrobial agent, (b) a disinfecting alcohol, and (c) (i) an organic acid, (ii) an inorganic salt comprising a cation having a valence of 2, 3, or 4 and a counterion capable of lowering a surface pH to about 5 or less, (iii) an aluminum, zirconium, or aluminum-zirconium complex, or (iv) mixtures thereof, wherein the composition has a pH of about 5 or less. | 2012-06-07 |
20120141601 | DIETARY SUPPLEMENT, FEED AND PHARMACEUTICAL COMPOSITION CONTAINING CHIA SEED AND MACA, AND PREPARATION METHOD THEREOF - Disclosed are a composition comprising chia seeds and maca, a dietary supplement or food additive, a feed and a pharmaceutical composition, all being based on the composition, and a method for preparing the dietary supplement, feed or pharmaceutical composition. The dietary supplement or food additive, the feed or feed additive, and the pharmaceutical composition exhibit can bring about excellent improvement in weight loss, sexual, gastrointestinal or hepatic function, male sex hormone release and endurance. In addition to a combination of chia seeds and maca, the composition, the food and the like may comprise optionally germanium, selenium or dietary zinc, and they are useful for the potentiation of sexual, gastrointestinal or hepatic functions, which leads to an improvement in weight loss, fatigue resistance, endurance, blood circulation, blood cholesterol level, anti-inflammation, immunity, sex hormone release, skin care, hangover cure, nicotine removal, breath care, body smell, invigoration and sterility. | 2012-06-07 |
20120141602 | SYSTEMS CONTAINING MAGNETIC NANOPARTICLES AND POLYMERS, SUCH AS NANOCOMPOSITES AND FERROFLUIDS, AND APPLICATIONS THEREOF - The present invention relates to a system comprising magnetic nanoparticles of a metal oxide and a polymer, which in turn contains monomers with different functional groups. This system can be solid (nanocomposite) or liquid (ferrofluid). The present invention also relates to a process for obtaining the system, as well as its use, mainly in biotechnological, veterinary and medical applications, such as, for example, for the diagnosis and treatment of human diseases. | 2012-06-07 |
20120141603 | METHODS AND COMPOSITIONS FOR LUNG CANCER PROGNOSIS - Disclosed herein are methods and materials for prognosing survival of lung cancer patients, the methods comprising the detection of gains and losses of minimal common regions and/or genes associated with prognosis and benefit of chemotherapy. | 2012-06-07 |